XASX
IDT
Market cap9mUSD
Jul 10, Last price
0.03AUD
1D
0.00%
1Q
-30.43%
Jan 2017
-82.22%
Name
IDT Australia Ltd
Chart & Performance
P/E
—
P/S
0.69
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.91%
Rev. gr., 5y
6.99%
Revenues
20m
+49.44%
Net income
-8m
L+48.96%
CFO
-6m
L-34.89%
Dividend
Apr 12, 20100.0097 AUD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company furnishes comprehensive analytical support, including the establishment of testing methodologies, stability assessments utilizing specialized chambers, and quality control laboratory services for both chemical and microbiological applications. Furthermore, its service offerings span project management, chemical processing, advanced analytical chemistry, pharmacy support, clinical trial packaging, and regulatory compliance assistance, alongside pharmaceutical development expertise across diverse dosage forms. Notably, IDT Australia also provides medicinal cannabis products and a broad array of contract manufacturing solutions. Established in 1975, the firm is headquartered in Boronia, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||